Alchemab Therapeutics

Company Overview

Alchemab Therapeutics is a biotech company developing novel antibody therapies using a patient-derived discovery approach. Its core strategy is to analyze the immune systems of individuals who show natural resistance to disease—such as long-term cancer survivors—and identify antibodies that confer protection.

The company applies deep B-cell sequencing, computational biology and machine learning to identify convergent antibody responses across patient populations. These antibodies are then developed into therapeutic candidates targeting the underlying biology of disease.

Alchemab operates as a platform-driven biotech, combining target discovery and therapeutic development within a single system. Its pipeline spans oncology, neurodegenerative disease and other areas where conventional approaches have been limited.

Headquarters and Global Presence

• headquartered in London, United Kingdom
• research operations supported by collaborations with global biobanks, academic institutions and patient groups

The company’s discovery engine depends on access to patient-derived biological data sourced internationally.

Founding and History

• founded in 2019 as a biotechnology startup focused on antibody discovery
• built on academic research into B-cell biology and antibody sequencing
• has raised over $100 million in venture funding across multiple rounds

The company has also entered into strategic collaborations with large pharmaceutical partners, including a licensing agreement with Eli Lilly to advance pipeline assets.

Therapy Areas and Focus

Alchemab develops therapies across diseases where natural immunity may reveal therapeutic mechanisms.

Key areas of focus include:

• neurodegenerative diseases such as ALS and Alzheimer’s disease
• oncology
• infectious diseases

The company prioritizes indications where patient-derived biology can uncover novel targets or mechanisms of protection.

Technology Platforms and Modalities

The company’s platform is based on patient-derived antibody discovery.

Key components include:

• deep sequencing of B-cell repertoires from resilient individuals
• identification of convergent protective antibody responses
• AI-enabled analysis of large antibody datasets
• development of monoclonal antibody therapeutics

This approach treats the adaptive immune system as a “search engine” for identifying biologically validated therapeutic targets.

Key Pipeline and Programs

ATLX-1282

• Modality: monoclonal antibody
• Indication focus: neurodegenerative disease (including ALS)
• Status: Phase I clinical development initiated in 2025

Additional antibody programs

• Modality: patient-derived monoclonal antibodies
• Indication focus: oncology, neurodegeneration and infectious disease
• Status: preclinical and discovery stage

The pipeline is generated from the company’s internal platform and includes both wholly owned and partnered assets.

Key Personnel

• Jane Osbourn, Chief Executive Officer

The leadership team includes scientists with backgrounds in antibody discovery, biologics development and translational medicine.

Strategic Partnerships

Alchemab operates with a partnership-driven model.

Key collaborations include:

• Eli Lilly, licensing and development partnership for antibody therapeutics
• collaborations with patient groups and biobanks providing biological samples
• venture investors including RA Capital, SV Health Investors and Ono Venture Investment

These relationships support both discovery and clinical development.

FAQ Section